Earnings Call · Q2 FY2023·2023-08-08

Q2 23EPS -22.73%·Rev n/aQ1 23EPS -4.46%·Rev n/aQ4 22EPS +28.89%·Rev n/aQ3 22EPS +28.90%·Rev n/a⚠ consensus missing

NEKTAR THERAPEUTICS NKTR

Vivian Wu — Investor Relations or Communications

Howard Robin — President and CEO

Dr. Jonathan Zalevsky — Chief of Research and Development

Dr. Mary Tagliaferri — Chief Medical Officer

Sandra Gardiner — Chief Financial Officer

−2.0%1d on move date−1.5% vs SPY3d+2.9%5d−19.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NKTR calls or request research access.

More NKTR calls Browse calls Request research access